In a report released on May 28, from Morgan Stanley maintained a Buy rating on Innovent Biologics, with a price target of HK$135.00. The compan...
Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$119.78.
The company has a one-year high of HK$109.10 and a one-year low of HK$60.85. Currently, Innovent Biologics has an average volume of 12.45M.
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Innovent, Pfizer sign oncology deal
Pfizer, Innovent Biologics sign $10.5bn cancer drug development deal
In a report released yesterday, from Zhongtai Securities maintained a Buy rating on Innovent Biologics, with a price target of…
CSC Financial analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$147.70.Memorial Day…
LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Inhibrx Biosciences Inc today and set a price target of…
LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Inhibikase Therapeutics today and set a price target of…
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to…
In a report released on May 28, from Morgan Stanley maintained a Buy rating on Keymed Biosciences, Inc., with a price target of…
